Clinical trial NCT05125341: Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China
Official title: Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Paroxysmal Nocturnal Hemoglobinuria, Natural History Study
Lead sponsor: CANbridge Life Sciences Ltd.
Sponsor class: INDUSTRY
First posted: 2021-11-18
Enrollment: 67
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis in China

Brief summary: This is a single-center observational study conducted in adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis.

This observational study consists of two parts, one part is retrospective study which aims to collect medical chart data to calculate the mean change or mean incidence rates of LDH, hemoglobin, PNH-related symptoms and PNH-related events over 6 months.

The other part is cross-sectional study to detect the total C5 level in PUMCH at the latest follow-up visit in eligible PNH patients with high-risk hemolysis, to show the difference between eligible PNH patients and healthy people and to explore the related clinical factor influencing high-level total C5 using logistic regression model.


Eligibility criteria: Inclusion Criteria:

1. Meet the diagnostic criteria for paroxysmal nocturnal hemoglobinuria;
2. Age ≥ 18 years old;
3. PNH clone size of granulocytes or monocytes (CD59 or Flaer) ≥ 10%;
4. LDH≥1.5 ULN;
5. Accompanied by at least one PNH-related symptoms: fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia symptoms, major adverse vascular events (including thrombosis), dysphagia, erectile dysfunction;
6. Transfusion-dependent PNH patients;
7. There are at least 6 months consecutive data of diagnosis and treatment after the data collection time point;
8. Patients agreed to participate in the study by signing informed consent or giving oral informed consent.

Exclusion Criteria:

1. Patients are under the treatment of the C1/C3/C5 complement inhibitors currently or in the past;
2. Patients have received bone marrow transplantation;
3. platelet count \<30\*10 9/L or absolute neutrophil count \<0.5\*10 9/L;
4. Patients have clinically significant heart, liver, or lung diseases, or have related medical history.
5. Patients have comorbidities of rheumatoid disease, HIV infection, active HBV infection, HCV infection and other diseases that affect the body's immune function;
6. Severe missing data in the records of diagnosis and treatment after the data collection time point;
7. Other patients who are not suitable to participate in the study.

Primary outcomes:
measure: the mean change of LDH
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
Study officials:
affiliation: Peking Union Medical College Hospital
name: Bing Han, MD
role: PRINCIPAL_INVESTIGATOR
References: